相关临床试验
52
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
5.8%
已完成
18
34.6%
尚未招募
10
19.2%
招募中
16
30.8%
终止
4
7.7%
撤回
1
1.9%
暂无批准数据
- AdvanCell will present the first clinical data for a Lead-212-based PSMA radioligand therapy at ESMO 2025, marking an important milestone in targeted alpha therapy development. - The Phase 1b dose escalation results from the TheraPb trial demonstrate a favorable safety profile and promising anti-tumor activity for ADVC001 in metastatic castration-resistant prostate cancer. - The presentation will feature updated safety and efficacy data from all seven Phase 1b treatment cohorts, with data cut-off as of May 9, 2025. - ADVC001 utilizes Lead-212, an alpha-emitting radionuclide with a 10.6-hour half-life, designed to deliver targeted radiation while minimizing toxicity.
- Australian researchers at The University of Queensland have dosed the first five participants in a groundbreaking clinical trial of ASITI-201, an immunotherapy designed to rebalance immune response in Type 1 diabetes. - The novel treatment combines pancreatic protein fragments with vitamin D to prevent immune attacks on insulin-producing cells, potentially preserving pancreatic function and reducing insulin dependence in recently diagnosed patients. - If successful, the therapy could fundamentally change treatment approaches by addressing the root cause of Type 1 diabetes, with future applications potentially including prevention in high-risk individuals and adaptation for other autoimmune conditions.
